InVenis Biotherapies is pleased to announce that it has received financial support from the ALS (Amyotrophic Lateral Sclerosis) patient advocacy organization for its flagship ALS program.
At the forefront of biotherapeutic research, relying on excellence of academic research, InVenis is developping a platelet-derived biotherapy for ALS. Commonly known as Charcot’s disease or Lou Gehrig's disease, ALS is a devastating neurodegenerative disorder that affects nerve cells in the brain and spinal cord, leading to the deterioration of muscle function, the inability to move and speak, respiratory paralysis and death.
Boris Molle, CEO "We are honored toreceive the endorsement of ARSLA, a vital advocate for ALS patients, encouraging research initiatives and providing resources for individuals and families affected by the disease. This award reflects our shared commitment to finding effective treatments for this challenging disease. »
InVenis Biotherapies is currently engaged in preclinical studies, with the goal of advancing its ALS treatment candidate towards human clinical trials.
About InVenis Biotherapies: InVenis Biotherapies is a preclinical-stage biotechnology company dedicated to the development of safe disease-modifying biotherapies for central nervous system (CNS) disorders. InVenis technology leverages the tissue healing and repair functions of platelets to deliver trophic factors to the CNS, enabling it to protect and regenerate itself.
About ARSLA: ARSLA (Association pour la Recherche sur la Sclérose Latérale Amyotrophique) is a non-profit organization committed to supporting research and initiatives aimed at finding effective treatments for Amyotrophic Lateral Sclerosis. Through advocacy and collaboration, ARSLA strives to improve the lives of individuals affected by ALS.
